消息面:现货黄金首次突破5200美元/盎司，年内累计涨幅超过20%。大规模冬季风暴引发美国天然气价 格飙涨，创三年来最高。多家品牌金饰克价大幅上调 老凤祥克价1620元。 欢迎您在评论中分享自己的看法，大家一起学习和讨论。 贵金属高开高走，截止午盘大涨10.26%，其中晓程科技20CM涨停，恒邦股份、招进黄金、四川黄金等 多股涨停。采掘行业、珠宝首饰、黄金概念、有色金属、稀缺资源等行业板块紧随其后，且涨幅均在 4%上方。 光伏设备低开低走陷入调整，截止午盘下跌2.74%，其中高测股份大跌8.1%，迈为股份、东方日升、泽 润新能等多股跌幅在7%上方。痘病毒防治、重组蛋白、生物制品、医疗器械等行业板块紧随其后，且 跌幅均在2%上方。 探底回升后回到中轴附近，截止午盘沪指上涨0.49%，深成指上涨0.09%，创业板指下跌0.37%。两市合 计超3500只个股上涨，合计成交额1.93万亿。 ...

Group 1 - The restructuring of the protein sector led to a decline of 1.42% [1] - Companies such as Baipusais fell by 7.3%, indicating significant losses within the sector [1] - Other companies like Nearshore Protein and Haitai Bio also experienced declines of 2.81% and 2.16% respectively [1] Group 2 - Sanofi Guojian saw a drop of over 3%, contributing to the overall downturn in the protein sector [1]

Market Overview - The A-share market experienced a collective pullback on January 13, with the Shanghai Composite Index ending a 17-day winning streak, closing down by 0.64% [1] - The Shenzhen Component Index fell by 1.37%, and the ChiNext Index decreased by 1.96%, with a total trading volume of 3.7 trillion yuan, setting a new historical record [1][2] Sector Performance - Multiple sectors faced significant declines, particularly in commercial aerospace and satellite internet, with nearly 100 stocks dropping over 8% [4] - The large aircraft and military sectors also saw declines, with stocks like Zhongtian Rocket and Leike Defense hitting the daily limit down [4] - The controlled nuclear fusion sector experienced a downturn, with Wangzi New Materials hitting the daily limit down [4] - The communication equipment sector fell, with stocks like Changjiang Communication hitting the daily limit down [4] Stock Movements - Over 1,600 stocks rose, with more than 70 stocks hitting the daily limit up [4] - The commercial aerospace concept stocks suffered heavy losses, with over 60 stocks hitting the daily limit down or dropping more than 10% [4] - Specific stocks such as Aerospace Electronics and Beidou Star Communication saw significant declines, with many military stocks also hitting the daily limit down [6] Investment Insights - The market sentiment has shifted from hesitation to active allocation, driven by a consensus on the current market rally [10] - Investors are advised to avoid speculative risks in popular sectors, particularly in commercial aerospace, and to focus on policy and industry resonance themes such as technological innovation and high-end manufacturing [11] - Key investment areas include sectors with performance support, such as overseas computing power, storage, consumer electronics, and wind energy storage, which still have room for low-cost allocation [10][11]

Core Viewpoint - The pharmaceutical sector experienced a rebound on November 11, with significant gains in various sub-sectors including chemical pharmaceuticals, innovative drugs, weight loss drugs, and recombinant proteins [2] Group 1: Sector Performance - The chemical pharmaceutical sector showed strong performance, contributing to the overall recovery of the pharmaceutical industry [2] - Innovative drugs also saw notable increases, indicating a positive market sentiment towards new drug developments [2] - Weight loss drugs and recombinant proteins were among the top gainers, reflecting growing consumer interest and demand in these areas [2] Group 2: Individual Stock Movements - Gendik rose over 15%, highlighting its strong market performance within the sector [2] - Hongyuan Pharmaceutical increased by more than 7%, indicating investor confidence in its growth prospects [2] - Other companies such as Nanjing New Pharmaceutical, Hendi Pharmaceutical, Haichen Pharmaceutical, and Tailong Pharmaceutical also experienced upward movements, suggesting a broader trend of recovery among pharmaceutical stocks [2]

Core Insights - The recombinant protein industry in China, despite its late start, has rapidly developed due to continuous support from national industrial policies, leading to significant breakthroughs in technology, production processes, and quality control [1][15] - The market for recombinant proteins is expected to grow steadily, driven by increased investment in innovative drug research, rising demand for precision medicine, and the expansion of downstream application scenarios [1][15] Industry Overview - Recombinant proteins are proteins obtained through genetic engineering and cell engineering, essential for the development and production of biopharmaceuticals, cell immunotherapy, and diagnostic reagents [4] - The industry has experienced three stages: the initial stage (1970-1990), rapid development (1990-2000), and transformation and upgrading (2000-present) [8][9] Market Growth - The market size of China's recombinant protein industry is projected to grow from 5.1 billion yuan in 2015 to 27 billion yuan in 2024, with a compound annual growth rate (CAGR) of 20.34% [1][15] - The global recombinant protein market is expected to increase from $7 billion in 2015 to $18.5 billion in 2024, with a CAGR of 11.4% [13][14] Policy Support - The Chinese government has implemented various policies to encourage technological innovation and market expansion in the biopharmaceutical sector, including funding support for research and expedited drug approval processes [9][10] Industry Chain - The upstream of the recombinant protein industry includes raw materials and equipment, while the midstream consists of recombinant protein products, and the downstream includes customers such as research institutions and pharmaceutical companies [10] Competitive Landscape - The recombinant protein market is characterized by a diverse and dynamic competitive landscape, with major multinational pharmaceutical companies like Pfizer, Roche, and Novartis leading the market, while numerous small and medium-sized enterprises focus on innovative technologies [16][17] Development Trends - The industry is moving towards high-end products, focusing on complex structures and high-value proteins, with an emphasis on product activity, purity, and consistency [18] - Intelligent technologies, including AI and machine learning, are expected to enhance research and production processes, improving efficiency and product quality [19][20] - Chinese recombinant protein companies are increasingly participating in global competition, aiming to meet international standards and establish a strong global presence [21]

Market Overview - Major A-share indices experienced slight fluctuations in the morning and rose in the afternoon, with the Shanghai Composite Index increasing by 1.22% to close at 3912.21 points, the Shenzhen Component Index rising by 1.73%, and the ChiNext Index up by 2.36% [1][2]. Trading Volume - The total market turnover reached 2.09 trillion yuan, a decrease of 506.2 billion yuan compared to the previous trading day, with over 4300 stocks rising [1]. Sector Performance - The robotics sector surged following the release of a document by Shanghai supporting the research and mass production of humanoid robots, with Sanhua Intelligent Control hitting the daily limit [3]. - The automotive sector also performed well, with Zhongtong Bus and Haima Automobile both reaching the daily limit [3]. - The recombinant protein and CRO sectors were active, led by Sai Sheng Pharmaceutical and Boteng Co., Ltd. [3]. - The aviation and airport sectors saw gains, with Huaxia Airlines hitting the daily limit [3]. - Other sectors with notable increases included high-pressure fast charging, Kirin batteries, precious metals, automotive parts, and chemical pharmaceuticals [3]. Declining Sectors - The shipping and port sector declined, with Nanjing Port dropping over 7% [3]. - The small metals and rare earth permanent magnet sectors retreated, with Galaxy Magnetic Materials leading the decline [3]. - The photolithography machine sector weakened, with New Lai Material falling over 12% [3]. - Other sectors with significant declines included grain concepts, genetically modified organisms, cultivated diamonds, and electronic chemicals [3].

Market Performance - Major A-share indices experienced slight fluctuations in the morning and surged in the afternoon, with the Shanghai Composite Index rising by 1.22% to 3912 points, the Shenzhen Component Index increasing by 1.73%, and the ChiNext Index climbing by 2.36% [1] - The total market turnover was 2.09 trillion yuan, a decrease of 506.2 billion yuan compared to the previous trading day, with over 4300 stocks rising [1] Sector Performance - The robotics sector saw gains following the issuance of a document by Shanghai supporting the research and mass production of humanoid robots, with Sanhua Intelligent Control hitting the daily limit [1] - The automotive sector also performed well, with Zhongtong Bus and Haima Automobile both reaching the daily limit [1] - The recombinant protein and CRO sectors were active, led by Sai Sheng Pharmaceutical and Boteng Co., Ltd. [1] - The aviation and airport sectors rose, with Huaxia Airlines hitting the daily limit [1] - Other sectors with notable gains included high-pressure fast charging, Kirin batteries, precious metals, automotive parts, and chemical pharmaceuticals [1] Declining Sectors - The shipping and port sector declined, with Nanjing Port dropping over 7% [1] - The small metals and rare earth permanent magnet sectors retreated, with Galaxy Magnetic Materials leading the decline [1] - The photolithography machine sector weakened, with Xinlai Materials falling over 12% [1] - Other sectors with significant declines included grain concepts, genetically modified organisms, cultivated diamonds, and electronic chemicals [1] Recent Fund Inflows - Recent net inflows were observed in sectors such as precious metals, engineering machinery, and electrical power networks, with respective increases of 2.93%, 3.26%, and 3.18% [2] - Other sectors with notable increases included motorcycles and electronic components, with increases of 2.70% and 2.68% respectively [2]

Core Viewpoint - The report outlines the continuous supervision and compliance of Suzhou Nearshore Protein Technology Co., Ltd. after its IPO on the Sci-Tech Innovation Board, emphasizing the company's adherence to regulations and its operational performance despite financial losses. Continuous Supervision Work - The sponsor has established a robust continuous supervision system and work plan for the company, ensuring compliance with relevant regulations and effective communication [1][2] - The sponsor conducted regular visits, due diligence, and checks to monitor the company's operations and compliance with laws and regulations [1][2] - Throughout the supervision period, the company did not encounter any violations or breaches of commitments that required public disclosure [1][2] Financial Performance - For the first half of 2025, the company reported revenue of approximately 72.09 million, a year-on-year increase of 20.85% [8] - The net loss attributable to shareholders was approximately 24.22 million, with a net profit excluding non-recurring items of about -26.68 million [8] - The company’s cash flow from operating activities was -14.08 million, indicating a significant decline compared to the previous year [8] Core Competitiveness - The company has developed seven comprehensive technology platforms and 23 core technologies, which are crucial for maintaining its market competitiveness [5][9] - The company emphasizes the importance of protecting its core technologies to prevent leakage, which could adversely affect its operations [5][9] - A skilled and stable technical team is essential for sustaining technological leadership and core competitiveness [5][9] Industry Risks - The RNA vaccine and drug industry is still maturing, with uncertainties in demand for mRNA raw materials and reagents in various applications [7][8] - The company faces intense competition from both domestic and international players, which could impact its market position and profitability [6][7] Research and Development - The company invested approximately 26.1 million in R&D in the first half of 2025, accounting for 36.21% of its revenue, reflecting a slight decrease from the previous year [16] - As of June 30, 2025, the company holds 38 invention patents, 22 utility model patents, and 18 software copyrights, indicating a strong focus on innovation [16] Use of Raised Funds - The company raised approximately 186.30 million through its IPO, with 174.22 million remaining after deducting issuance costs, and has complied with regulations regarding the use of these funds [17][18]

Group 1 - The restructuring protein sector is leading the market with an increase of 3.07% [1] - Key companies in this sector include Kaiyin Technology, which rose by 8.7%, and Saiseng Pharmaceutical, which increased by 7.3% [1] - Other notable performers are Maiwei Biotechnology with a rise of 6.86%, and Baipusais, Hite Biotechnology, and Ruizhi Pharmaceutical, all of which saw gains exceeding 4% [1]

Market Performance - The three major A-share indices opened higher and maintained a fluctuating upward trend, reaching new highs for the year [1] - By the close, the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index rose by 0.5%, 0.53%, and 1.24% respectively, closing at 3665.92 points, 11351.63 points, and 2409.4 points [1] Sector Performance - The semiconductor sector showed strong performance, with Cambrian Technology hitting the daily limit and reaching a historical high [1] - Other sectors such as brain engineering, diversified finance, and electronic chemicals also saw significant gains, while aerospace, recombinant proteins, and minor metals experienced declines [1] Stock Performance - A total of 2084 stocks in A-shares rose, with 60 stocks hitting the daily limit, while 3167 stocks fell, including 5 stocks hitting the lower limit [1] Trading Volume - The trading volume in the Shanghai market was approximately 778.16 billion yuan, while the Shenzhen market's trading volume was about 1.103359 trillion yuan, leading to a combined trading volume of around 1.88 trillion yuan [1]